These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 3465872

  • 21. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA, Burns RS, Calne DB.
    Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
    [Abstract] [Full Text] [Related]

  • 22. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG, Carter JH, Lea ES, Woodward WR.
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Continuous dopaminergic stimulation in Parkinson disease].
    Obeso JA, Luquin MR, Vaamonde J, Grandas F, Pastor MA, Artieda J, Martínez-Lage JM.
    Neurologia; 1987 May; 2(5):227-34. PubMed ID: 2908545
    [No Abstract] [Full Text] [Related]

  • 29. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A, Trenkwalder C, Oehlwein C, Winkelmann J, Polzer U, Hundemer HP, Schwarz J.
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [Abstract] [Full Text] [Related]

  • 30. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 31. Efficacy of a low-dose subcutaneous lisuride infusion in Parkinson's disease.
    Hayashi R, Tako K, Makishita H, Koyama J, Yanagisawa N.
    Intern Med; 1998 May; 37(5):444-8. PubMed ID: 9652898
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H.
    Neurology; 2005 Jan 25; 64(2):216-23. PubMed ID: 15668416
    [Abstract] [Full Text] [Related]

  • 37. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R, Lees AJ.
    J Neurol; 2002 Sep 25; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.